Startups
Gensaic
Cambridge, Massachusetts, United States
Cambridge, Massachusetts biotechnology company founded by Lavi Erisson, Uyanga Tsedev and Jonathan Hsu in 2021 as an MIT spinout, formerly M13 Therapeutics. Its FORGE Engine combines protein language models, sequence-to-function experiments and AI-assisted gene-pair discovery to design tissue-selective delivery ligands and multifunctional siRNA conjugates. Current programs target obesity with lean-mass preservation, obesity with MASH, and cardiometabolic disease, all in preclinical discovery or lead optimization. Earlier phage-derived gene delivery work included rare CNS targets with Ovid Therapeutics and CFTR delivery with the Cystic Fibrosis Foundation. Ovid invested through equity and a convertible note; its CNS collaboration was amended in January 2026. Gensaic also has a tissue-targeting discovery collaboration with Novo Nordisk and an NIH muscle gene delivery grant. Potential commercial milestones and conditional foundation commitments are distinct from completed equity financing.
Founded 2021
Team
 Alex WangSenior Scientist |
 Emanuel BurgosComputational Biologist |
 Evans WralstadSenior Scientist |
 Gabrielle Mitchell-LeeSenior Research Associate |
 Jeremy LevinChairman |
Jill MilneBoard Member |
 Jonathan HsuChief Technology Officer and Co-Founder |
 Jonathan SandsSenior Research Associate |
Karina ThornBoard Observer |
 Lavi ErissonChief Executive Officer and Co-Founder · Board Member |
Liang SchweizerBoard Member |
 Maggie LejeuneAssociate Scientist |
 Maya OrzachSenior Research Associate |
Nathan Higginson-ScottChief Research and Development Officer (appointed January 2026) |
 Neil ExterBoard Member |
 Neo RuizResearch Associate |
 Sungmin BaekSenior Scientist |
 Uyanga TsedevChief Scientific Officer and Co-Founder |